BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1125 related articles for article (PubMed ID: 29420467)

  • 1. HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
    Hyman DM; Piha-Paul SA; Won H; Rodon J; Saura C; Shapiro GI; Juric D; Quinn DI; Moreno V; Doger B; Mayer IA; Boni V; Calvo E; Loi S; Lockhart AC; Erinjeri JP; Scaltriti M; Ulaner GA; Patel J; Tang J; Beer H; Selcuklu SD; Hanrahan AJ; Bouvier N; Melcer M; Murali R; Schram AM; Smyth LM; Jhaveri K; Li BT; Drilon A; Harding JJ; Iyer G; Taylor BS; Berger MF; Cutler RE; Xu F; Butturini A; Eli LD; Mann G; Farrell C; Lalani AS; Bryce RP; Arteaga CL; Meric-Bernstam F; Baselga J; Solit DB
    Nature; 2018 Feb; 554(7691):189-194. PubMed ID: 29420467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
    Hanker AB; Brown BP; Meiler J; Marín A; Jayanthan HS; Ye D; Lin CC; Akamatsu H; Lee KM; Chatterjee S; Sudhan DR; Servetto A; Brewer MR; Koch JP; Sheehan JH; He J; Lalani AS; Arteaga CL
    Cancer Cell; 2021 Aug; 39(8):1099-1114.e8. PubMed ID: 34171264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Determinants of Response to HER Kinase Inhibition in
    Smyth LM; Piha-Paul SA; Won HH; Schram AM; Saura C; Loi S; Lu J; Shapiro GI; Juric D; Mayer IA; Arteaga CL; de la Fuente MI; Brufksy AM; Spanggaard I; Mau-Sørensen M; Arnedos M; Moreno V; Boni V; Sohn J; Schwartzberg LS; Gonzàlez-Farré X; Cervantes A; Bidard FC; Gorelick AN; Lanman RB; Nagy RJ; Ulaner GA; Chandarlapaty S; Jhaveri K; Gavrila EI; Zimel C; Selcuklu SD; Melcer M; Samoila A; Cai Y; Scaltriti M; Mann G; Xu F; Eli LD; Dujka M; Lalani AS; Bryce R; Baselga J; Taylor BS; Solit DB; Meric-Bernstam F; Hyman DM
    Cancer Discov; 2020 Feb; 10(2):198-213. PubMed ID: 31806627
    [No Abstract]   [Full Text] [Related]  

  • 4. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.
    Verlingue L; Hollebecque A; Lacroix L; Postel-Vinay S; Varga A; El Dakdouki Y; Baldini C; Balheda R; Gazzah A; Michot JM; Marabelle A; Mir O; Arnedos M; Rouleau E; Solary E; De Baere T; Angevin E; Armand JP; Michiels S; André F; Deutsch E; Scoazec JY; Soria JC; Massard C
    Eur J Cancer; 2018 Mar; 92():1-10. PubMed ID: 29413684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.
    Oaknin A; Friedman CF; Roman LD; D'Souza A; Brana I; Bidard FC; Goldman J; Alvarez EA; Boni V; ElNaggar AC; Passalacqua R; Do KTM; Santin AD; Keyvanjah K; Xu F; Eli LD; Lalani AS; Bryce RP; Hyman DM; Meric-Bernstam F; Solit DB; Monk BJ
    Gynecol Oncol; 2020 Oct; 159(1):150-156. PubMed ID: 32723675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
    Harding JJ; Piha-Paul SA; Shah RH; Murphy JJ; Cleary JM; Shapiro GI; Quinn DI; Braña I; Moreno V; Borad M; Loi S; Spanggaard I; Park H; Ford JM; Arnedos M; Stemmer SM; de la Fouchardiere C; Fountzilas C; Zhang J; DiPrimeo D; Savin C; Duygu Selcuklu S; Berger MF; Eli LD; Meric-Bernstam F; Jhaveri K; Solit DB; Abou-Alfa GK
    Nat Commun; 2023 Feb; 14(1):630. PubMed ID: 36746967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Blockade of Activating
    Croessmann S; Formisano L; Kinch LN; Gonzalez-Ericsson PI; Sudhan DR; Nagy RJ; Mathew A; Bernicker EH; Cristofanilli M; He J; Cutler RE; Lalani AS; Miller VA; Lanman RB; Grishin NV; Arteaga CL
    Clin Cancer Res; 2019 Jan; 25(1):277-289. PubMed ID: 30314968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.
    Kiavue N; Cabel L; Melaabi S; Bataillon G; Callens C; Lerebours F; Pierga JY; Bidard FC
    Oncogene; 2020 Jan; 39(3):487-502. PubMed ID: 31519989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Acquired
    Hanker AB; Brewer MR; Sheehan JH; Koch JP; Sliwoski GR; Nagy R; Lanman R; Berger MF; Hyman DM; Solit DB; He J; Miller V; Cutler RE; Lalani AS; Cross D; Lovly CM; Meiler J; Arteaga CL
    Cancer Discov; 2017 Jun; 7(6):575-585. PubMed ID: 28274957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
    Choi BK; Fan X; Deng H; Zhang N; An Z
    Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
    Friedman CF; D'Souza A; Bello Roufai D; Tinker AV; de Miguel M; Gambardella V; Goldman J; Loi S; Melisko ME; Oaknin A; Spanggaard I; Shapiro GI; ElNaggar AC; Panni S; Ravichandran V; Frazier AL; DiPrimeo D; Eli LD; Solit DB
    Gynecol Oncol; 2024 Feb; 181():162-169. PubMed ID: 38211393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [SUMMIT: a basket study scores points].
    Luscan A; Pasmant É
    Med Sci (Paris); 2018 Nov; 34(11):910-913. PubMed ID: 30526831
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib.
    Ulaner GA; Saura C; Piha-Paul SA; Mayer I; Quinn D; Jhaveri K; Stone B; Shahin S; Mann G; Dujka M; Bryce R; Meric-Bernstam F; Solit DB; Hyman DM
    Clin Cancer Res; 2019 Dec; 25(24):7381-7387. PubMed ID: 31548342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HER3/ErbB3 receptor: a promising target in cancer drug therapy.
    Desbois-Mouthon C
    Gastroenterol Clin Biol; 2010; 34(4-5):255-9. PubMed ID: 20418034
    [No Abstract]   [Full Text] [Related]  

  • 15. Update on HER-kinase-directed therapy in prostate cancer.
    Gross ME; Jo S; Agus DB
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
    Schneeweiss A; Park-Simon TW; Albanell J; Lassen U; Cortés J; Dieras V; May M; Schindler C; Marmé F; Cejalvo JM; Martinez-Garcia M; Gonzalez I; Lopez-Martin J; Welt A; Levy C; Joly F; Michielin F; Jacob W; Adessi C; Moisan A; Meneses-Lorente G; Racek T; James I; Ceppi M; Hasmann M; Weisser M; Cervantes A
    Invest New Drugs; 2018 Oct; 36(5):848-859. PubMed ID: 29349598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
    Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM
    Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.
    Baselga J; Swain SM
    Nat Rev Cancer; 2009 Jul; 9(7):463-75. PubMed ID: 19536107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
    Tiwari SR; Mishra P; Abraham J
    Clin Breast Cancer; 2016 Oct; 16(5):344-348. PubMed ID: 27405796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
    Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
    Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.